StockWatch
·

Fine Organic Industries Ltd Q3 FY26 Results

FINEORGQ3 FY26 Results
Filing
MetricValue ( Cr)Q2 FY26Q3 FY25
Revenue554.807.1%8.1%
Total Income575.936.9%6.2%
Expenditure474.670.1%11.0%
PBT101.2729.2%11.7%
Net Profit73.9331.9%10.6%
OPM17.01%5.62pp2.96pp
NPM12.84%4.71pp2.41pp
EPS24.1131.9%10.6%
View full financials

Fine Organic Industries Announces Q3FY26 and 9MFY26 Results with 47% YoY Revenue Growth

13 Feb 2026 · 13 Feb, 4:43 pm

Summary

Fine Organic Industries, the largest manufacturer of oleochemical-based additives in India, has announced its financial results for the Quarter and nine months ended 31st December 2025. The company reported a 47% YoY revenue growth.

Key Highlights

  1. 1

    Q3FY26 revenue was INR 554.8 crores, a 59.73% QoQ growth

  2. 2

    9MFY26 revenue was INR 1,740.5 crores, a 47% YoY growth

  3. 3

    Exports accounted for around 53% of total revenue in Q3 FY26

  4. 4

    Raw material prices increased in FY26 compared to FY25

  5. 5

    Freight costs have stabilized and reduced during the year

  6. 6

    The Government of India has notified the implementation of four new Labour Codes effective November 21%, 2025

  7. 7

    The Company infused equity of about INR 6.17 crores in its Joint Venture company Fine Organic Industries (Thailand) Co. Ltd.

  8. 8

    Fine Organic Industries Limited has incorporated a wholly owned subsidiary, Fine Organics FZE, in Dubai, UAE

  9. 9

    In Q2FY26, the WOS Company issued Preference Shares amounting to INR 65 crores as part of its equity capital structure

  10. 10

    In Q2FY26, the Company incorporated a wholly owned subsidiary, Fine Organics Americas LLC, in the United States to set up a manufacturing plant

Management Comments

N

Not specified

Fine Organic Industries Limited, the largest manufacturer of oleochemical-based additives in India, has announced its financial results for the Quarter and nine months ended 31st December 2025. The company reported a 47% YoY revenue growth.

Informational and educational content only. Not investment advice.